


Pandemic Influenza Preparedness Strategy and Plan



- International Surveillance
- Domestic Surveillance
- Vaccine
- Antivirals
- Communications
- State and Local Preparedness

Pandemic Vaccine Evaluation Preliminary Results

- Sanofi Inactivated H5N1 Subunit Vaccine
 - Evaluated in 451 healthy young adults; well-tolerated overall
 - Two 90 µg doses induced an immune response predictive of protection
- Chiron Inactivated H9N2 Subunit Vaccine with MF59 Adjuvant
 - Evaluated in 96 healthy young adults; well-tolerated overall
 - Single 3.75 µg dose induced an immune response predictive of protection

Influenza Vaccines: Stockpile and Strategy


Stockpile:

- Bulk H5N1 vaccine contracts (90µg doses):
 - 0.4 M doses - Sanofi 2004
 - 6.2 M doses - Sanofi 2005
 - 2.0 M doses - Chiron 2005-2006
- 8.6 M doses total for 4.3 million people

Strategy:

- Manufacture 20 million courses of pre-pandemic vaccine
- Create capacity to manufacture 300 million courses of vaccine within six months of pandemic outbreak

Antiviral Therapies for Influenza



Influenza Treatments: Stockpile and Strategy

Stockpile:

- Tamiflu: 4.3 million courses in Strategic National Stockpile with an additional 1 million courses by end of January 2006

Strategy:

- Procure 81 million courses of antivirals
 - 6 million courses to be used to contain an initial U.S. outbreak
 - 75 million courses to treat 25 percent of U.S. population
- Accelerate development of promising new antiviral candidates

Seasonal Influenza Preparedness



Pandemic Influenza Preparedness